Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (NASDAQ: LTRN) announced significant operational highlights and financial results for the fourth quarter and fiscal year 2022. The Harmonic™ clinical trial for never-smoker patients with non-small cell lung cancer (NSCLC) has activated 5 clinical sites across 12 locations, with patient enrollment expected in Q2 2023. The company also completed IND-enabling studies for drug candidates LP-184 and LP-284, with IND submissions planned for April and mid-2023, respectively. Lantern reported a cash position of
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in the AACR Annual Meeting from April 14-19, 2023 in Orlando, FL. The company will present a poster titled LP-184, an acylfulvene class small molecule therapeutic, focusing on its synthetic lethality mechanism targeting DNA damage repair deficient cancers, affecting 25-30% of solid tumors. The presentation is scheduled for April 19, 2023, 9:00 a.m. – 12:30 p.m. ET. Lantern aims to advance LP-184 to a Phase 1 clinical trial by mid-2023. Additionally, a webinar on synthetic lethality will be held on March 21, 2023 featuring expert Zoltan Szallasi.
Lantern Pharma Inc. (NASDAQ: LTRN) announced a webcast on March 20, 2023, at 4:30 p.m. ET, to disclose its fourth quarter and fiscal year 2022 financial results. Management, led by CEO Panna Sharma, will discuss operating and financial metrics for the fiscal year ended December 31, 2022 and outline upcoming milestones. Lantern Pharma is focused on oncology and leverages its proprietary RADR® AI platform to enhance drug discovery methods.
A replay will be available post-call on their investor relations website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced that it has no exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank, ensuring its financial stability. The company’s cash, cash equivalents, and marketable securities are managed through top-tier financial institutions, providing sufficient resources to support operations and development through 2025. Lantern Pharma utilizes its proprietary RADR® AI platform to enhance oncology drug discovery, focusing on genomic profiling to identify patients likely to benefit from its therapeutics. This strategic approach aims to improve treatment outcomes for cancer patients.
Lantern Pharma (NASDAQ: LTRN) announced new findings supporting the development of LP-100 combined with PARP inhibitors for treating metastatic prostate cancer and other indications. Synergistic effects were observed in studies using LP-100 alongside notable PARP agents like Olaparib. Preliminary Phase 2 trial data indicated a median overall survival of 12.5 months for nine patients in Denmark, better than comparable treatment regimens. Future market potential for LP-100 is estimated between $700 million and $2 billion. This strategic focus aims to maximize LP-100's market opportunities while enhancing treatment pathways for patients with specific gene mutations.
Lantern Pharma (NASDAQ: LTRN) will host a virtual key opinion leader (KOL) webinar on March 21, 2023, at 12:00 p.m. ET, focusing on synthetic lethality in oncology. Dr. Zoltan Szallasi, a prominent expert, will discuss the mechanism of action behind Lantern's drug candidate LP-184 and its implications for solid tumors. Attendees will learn about the history of synthetic lethality, how it targets DNA damage repair deficiencies, and LP-184's potential to enhance cancer treatments. Registration is available here. A replay will be accessible on Lantern's website following the event.
Lantern Pharma (NASDAQ: LTRN) announces the formation of a wholly-owned subsidiary, Starlight Therapeutics, focused on developing therapies for CNS and brain cancers. Leveraging the RADR® AI platform, Starlight's lead candidate, STAR-001, shows promising results in in-vitro and in-vivo studies, demonstrating blood-brain barrier permeability and nanomolar potency. Clinical trials are expected in late 2023 and early 2024 for indications with over 500,000 new cases annually and a market potential exceeding
Lantern Pharma (NASDAQ: LTRN) has expanded its clinical development team, appointing Dr. Reggie Ewesuedo as Vice President of Clinical Development. This strategic move aims to advance the ongoing Harmonic™ trial for non-small cell lung cancer (NSCLC) and initiate first-in-human Phase 1 trials for drug candidates LP-184 and LP-284, projected to launch in mid-2023. Dr. Ewesuedo brings over 20 years of experience in drug development, enhancing the company's capabilities in oncology. The team also welcomes Ernest Kitt as Head of Clinical Operations and other professionals to bolster their clinical efforts.
Lantern Pharma announced a collaboration with TTC Oncology to utilize its AI platform, RADR®, in advancing the clinical development of TTC-352, a selective human estrogen receptor partial agonist (ShERPA) for metastatic ER+ breast cancer. This innovative drug candidate is positioned as first-in-class, targeting patients who have failed previous therapies. As part of the agreement, Lantern gains exclusive licensing rights to TTC-352 and any resulting intellectual property. The partnership aims to leverage over 25 billion oncology-focused data points and advanced machine learning algorithms for patient selection and drug development insights, enhancing potential market reach.
Lantern Pharma Inc. (NASDAQ: LTRN) is enhancing its RADR® platform to support the development of Antibody Drug Conjugates (ADCs). This initiative aims to advance ADC candidates to first-in-human trials in around two years, bolstered by a library of over 200 algorithms and 25 billion oncology-focused data points. The ADC market, currently valued at over $4 billion, is projected to grow to $14 billion by 2027. The expansion includes new AI and ML strategies for drug candidate identification, patient stratification, and improved payload delivery, positioning Lantern for significant business development opportunities.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
